CN104903301B - 可用于调节IL‑12、IL‑23和/或IFNα的烷基酰胺取代的嘧啶化合物 - Google Patents

可用于调节IL‑12、IL‑23和/或IFNα的烷基酰胺取代的嘧啶化合物 Download PDF

Info

Publication number
CN104903301B
CN104903301B CN201380069688.2A CN201380069688A CN104903301B CN 104903301 B CN104903301 B CN 104903301B CN 201380069688 A CN201380069688 A CN 201380069688A CN 104903301 B CN104903301 B CN 104903301B
Authority
CN
China
Prior art keywords
substituted
disease
compounds
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380069688.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104903301A (zh
Inventor
J.B.桑特拉
R.M.莫斯林
D.S.魏因施泰因
S.T.弗罗布列夫斯基
J.S.托卡斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN104903301A publication Critical patent/CN104903301A/zh
Application granted granted Critical
Publication of CN104903301B publication Critical patent/CN104903301B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201380069688.2A 2012-11-08 2013-11-07 可用于调节IL‑12、IL‑23和/或IFNα的烷基酰胺取代的嘧啶化合物 Active CN104903301B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723827P 2012-11-08 2012-11-08
US61/723827 2012-11-08
PCT/US2013/068866 WO2014074670A1 (en) 2012-11-08 2013-11-07 ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα

Publications (2)

Publication Number Publication Date
CN104903301A CN104903301A (zh) 2015-09-09
CN104903301B true CN104903301B (zh) 2017-08-29

Family

ID=49667570

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380069688.2A Active CN104903301B (zh) 2012-11-08 2013-11-07 可用于调节IL‑12、IL‑23和/或IFNα的烷基酰胺取代的嘧啶化合物

Country Status (14)

Country Link
US (1) US9540333B2 (enExample)
EP (1) EP2917186B1 (enExample)
JP (1) JP6266639B2 (enExample)
KR (1) KR102205914B1 (enExample)
CN (1) CN104903301B (enExample)
AU (1) AU2013341195B2 (enExample)
BR (1) BR112015009798A2 (enExample)
CA (1) CA2890935A1 (enExample)
EA (1) EA028052B1 (enExample)
ES (1) ES2648226T3 (enExample)
IL (1) IL238605A (enExample)
MX (1) MX2015005561A (enExample)
SG (1) SG11201503395TA (enExample)
WO (1) WO2014074670A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013341186B2 (en) 2012-11-08 2017-03-30 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
EP3080131B1 (en) 2013-12-10 2018-10-10 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
KR102477063B1 (ko) * 2016-10-28 2022-12-12 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물
TWI733982B (zh) 2017-02-16 2021-07-21 美商基利科學股份有限公司 吡咯并[1,2-b]嗒衍生物
CN107857754B (zh) * 2018-01-15 2018-11-09 泰山医学院 一种化合物及其在制备预防/治疗类风湿性关节炎药物中的应用
US10508113B2 (en) 2018-03-12 2019-12-17 Abbvie Inc. Inhibitors of tyrosine kinase 2 mediated signaling
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
CN114269336A (zh) 2019-04-30 2022-04-01 细胞基因公司 包含阿普斯特和tyk2抑制剂的联合疗法
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
CA3207819A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
JP2024507253A (ja) 2021-02-19 2024-02-16 スドー バイオサイエンシーズ リミテッド Ｔｙｋ２阻害剤およびその使用
JP2024508794A (ja) 2021-02-19 2024-02-28 スドー バイオサイエンシーズ リミテッド Ｔｙｋ２阻害剤およびその使用
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
WO2024257023A1 (en) 2023-06-14 2024-12-19 Alembic Pharmaceuticals Limited Tyk2 pseudokinase ligands and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1518855A1 (en) * 2002-06-28 2005-03-30 Yamanouchi Pharmaceutical Co. Ltd. Diaminopyrimidinecarboxa mide derivative
CN101027288A (zh) * 2004-09-30 2007-08-29 泰博特克药品有限公司 抑制hiv的5－取代嘧啶
CN101405283A (zh) * 2006-03-30 2009-04-08 泰博特克药品有限公司 Hiv抑制性5-酰氨基取代的嘧啶类化合物
WO2011065800A2 (ko) * 2009-11-30 2011-06-03 주식회사 오스코텍 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
CN102421762A (zh) * 2009-03-18 2012-04-18 贝林格尔.英格海姆国际有限公司 用于治疗癌症的取代的嘧啶
WO2012145569A1 (en) * 2011-04-22 2012-10-26 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
KR20050019797A (ko) * 2002-06-28 2005-03-03 야마노우치세이야쿠 가부시키가이샤 디아미노피리미딘카르복사미드 유도체
JP5095409B2 (ja) * 2004-11-24 2012-12-12 ライジェル ファーマシューティカルズ， インコーポレイテッド スピロ２，４−ピリミジンジアミン化合物およびその使用
CA2657260A1 (en) * 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
KR20100132550A (ko) * 2008-04-16 2010-12-17 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드
JP5705720B2 (ja) * 2008-04-16 2015-04-22 ポートラ ファーマシューティカルズ， インコーポレイテッド Ｓｙｋまたはｊａｋキナーゼ阻害剤としての２，６−ジアミノ−ピリミジン−５−イル−カルボキサミド
US8367689B2 (en) * 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
JP2012529535A (ja) * 2009-06-12 2012-11-22 ブリストル−マイヤーズ スクイブ カンパニー キナーゼモジュレーターとして有用なニコチンアミド化合物
AR093403A1 (es) 2012-11-08 2015-06-03 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa
AU2013341186B2 (en) 2012-11-08 2017-03-30 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
AR094537A1 (es) 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1518855A1 (en) * 2002-06-28 2005-03-30 Yamanouchi Pharmaceutical Co. Ltd. Diaminopyrimidinecarboxa mide derivative
CN101027288A (zh) * 2004-09-30 2007-08-29 泰博特克药品有限公司 抑制hiv的5－取代嘧啶
CN101405283A (zh) * 2006-03-30 2009-04-08 泰博特克药品有限公司 Hiv抑制性5-酰氨基取代的嘧啶类化合物
CN102421762A (zh) * 2009-03-18 2012-04-18 贝林格尔.英格海姆国际有限公司 用于治疗癌症的取代的嘧啶
WO2011065800A2 (ko) * 2009-11-30 2011-06-03 주식회사 오스코텍 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
WO2012145569A1 (en) * 2011-04-22 2012-10-26 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthetic studies on novel Sykin hibitors. Part1: Synthesis and structure–activity relationships of pyrimidine-5-carboxamide derivatives;Hiroyuki Hisamichi et al;《Bioorganic & Medicinal Chemistry》;20050815;第13卷(第16期);第4936-4951页，第4939页Scheme 3化合物14e， *

Also Published As

Publication number Publication date
EA028052B1 (ru) 2017-10-31
JP2016501185A (ja) 2016-01-18
IL238605A (en) 2017-05-29
CN104903301A (zh) 2015-09-09
EA201590911A1 (ru) 2015-10-30
US9540333B2 (en) 2017-01-10
KR20150079678A (ko) 2015-07-08
BR112015009798A2 (pt) 2017-07-11
EP2917186A1 (en) 2015-09-16
WO2014074670A1 (en) 2014-05-15
KR102205914B1 (ko) 2021-01-20
JP6266639B2 (ja) 2018-01-24
US20150299139A1 (en) 2015-10-22
MX2015005561A (es) 2015-07-23
CA2890935A1 (en) 2014-05-15
AU2013341195B2 (en) 2017-09-21
ES2648226T3 (es) 2017-12-29
SG11201503395TA (en) 2015-05-28
AU2013341195A1 (en) 2015-07-02
EP2917186B1 (en) 2017-10-18
IL238605A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
JP7490107B2 (ja) スルホンピリジンアルキルアミド置換ヘテロアリール化合物
KR102531036B1 (ko) Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
JP6312823B2 (ja) Ｉｌ−１２、ｉｌ−２３および／またはｉｆｎアルファ応答の調節因子として有用なアルキル−アミド−置換ピリジル化合物
JP6266639B2 (ja) ＩＬ−１２、ＩＬ−２３および／またはＩＦＮαの調節に有用なアルキルアミド置換ピリミジン化合物
ES3035735T3 (en) Amide-disubstituted pyridine or pyridazine compounds
KR102602558B1 (ko) Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서의 포스핀 옥시드 알킬 아미드 치환된 헤테로아릴 화합물
JP2019501125A (ja) ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物
KR20240008337A (ko) 치환된 헤테로시클릭 화합물
JP2019535723A (ja) Ｉｌ−１２、ｉｌ−２３および／またはｉｆｎ−アルファのイミダゾピリダジン調節剤
CN114222744B (zh) 可用作IL-12、IL-23和/或IFNα反应调节剂的咪唑并哒嗪化合物
CN117279906A (zh) 经取代的杂环化合物
EA046543B1 (ru) Амидзамещенные гетероциклические соединения

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant